FDA Accelerated Approval Review Asks If Reg Gives De Facto Exclusivity
Executive Summary
FDA's reassessment of its accelerated approval regulations includes consideration of whether the current rule creates a de facto market exclusivity that discourages research
You may also be interested in...
FDA Revising Accelerated Approval Standard In Oncology; Biomarkers Sought
FDA is changing its accelerated approval guidelines to allow for approval of several different oncologic agents for the same indication under Subpart H procedures, Commissioner McClellan said during the American Society of Clinical Oncology annual meeting in Chicago May 31
FDA Revising Accelerated Approval Standard In Oncology; Biomarkers Sought
FDA is changing its accelerated approval guidelines to allow for approval of several different oncologic agents for the same indication under Subpart H procedures, Commissioner McClellan said during the American Society of Clinical Oncology annual meeting in Chicago May 31
Iressa User Fee Date Pushed To May; Will Advisory Cmte. Take Second Look?
FDA will take regulatory action on AstraZeneca's Iressa (gefitinib) by May 5